|Bid||252.47 x 800|
|Ask||252.55 x 900|
|Day's Range||248.85 - 253.83|
|52 Week Range||173.12 - 264.97|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||19.76|
|Earnings Date||Jul 28, 2020|
|Forward Dividend & Yield||6.40 (2.54%)|
|Ex-Dividend Date||May 15, 2020|
|1y Target Est||255.25|
If you want to know who really controls Amgen Inc. (NASDAQ:AMGN), then you'll have to look at the makeup of its share...
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
After notching a roughly 18% gain in April and May, the S&P 500 has gained only about 2% since early June. Here are Barron’s picks for S&P 500 stocks with attractive, but not ultrahigh, dividend yields.
We have publicly tracked our portfolio since 2015, which has beaten the S&P; 500 in terms of total return over this period of time. Most importantly, dividend income continues to grow Continue reading...
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Amgen stock broke out amid a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. So, is Amgen stock a buy now?
The Zacks Analyst Blog Highlights: Netflix, Exxon Mobil, Amgen, Humana and FedEx
Top Research Reports for Netflix, Exxon Mobil & Amgen
Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
The S&P 500 and Nasdaq indexes closed higher on Wednesday to kick off the third quarter as increasing optimism for a safe and effective COVID-19 vaccine eased concerns that another round of business lockdowns was likely. Pfizer Inc's shares rose more than 3% after the drugmaker said a COVID-19 vaccine being developed with German biotech firm BioNTech showed promise and was found to be well-tolerated in early-stage human trials.
The first half of 2020 was turbulent, but it was generally good to the Nasdaq stock market, and that momentum continued on the first day of July. The Nasdaq Composite (NASDAQINDEX: ^IXIC) and the Nasdaq 100 climbed around 1%, outpacing much of the rest of the market. Amgen (NASDAQ: AMGN) celebrated a valuable legal win, while Netflix (NASDAQ: NFLX) made a strategic hire and got praise from stock analysts.
What happened Shares of Amgen (NASDAQ: AMGN) were jumping 8.4% higher as of 3:09 p.m. EDT on Wednesday. The nice gain came after a U.S. appeals court ruled in Amgen's favor in a case challenging the validity of two patents for immunology drug Enbrel.
U.S. stocks moved higher on Wednesday as rising hopes of a safe and effective COVID-19 vaccine eased concerns another round of lockdowns was likely following a record surge in coronavirus cases in the United States. Pfizer Inc's shares rose nearly 5% after the drugmaker said a COVID-19 vaccine being developed with German biotech firm BioNTech showed promise and was found to be well-tolerated in early-stage human trials.
The Dow Jones wasn't moving much in afternoon trading Wednesday, but Pfizer stock rose sharply on positive coronavirus vaccine data.
Wall Street's main indexes gained on Wednesday as rising hopes of a safe and effective COVID-19 vaccine allayed some fears of another round of lockdowns following a record surge in coronavirus cases in the United States. A COVID-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trials, the companies said. Pfizer's shares rose about 5% on the news, one of the biggest boost to the S&P 500 index, while BioNTech gained 7%, helping improve the mood on Wall Street after the United States registered 47,000 new coronavirus cases on Tuesday, the biggest one-day spike since the start of the pandemic.
The S&P 500 and Nasdaq rose on Wednesday as rising hopes of a COVID-19 vaccine offset fears of another round of lockdowns following a record surge in coronavirus cases in the United States. A COVID-19 vaccine developed by Pfizer Inc and German biotech firm BioNTech showed promise and was found to be well tolerated in early-stage human trial, the companies said.
Amgen today announced that the United States Court of Appeals for the Federal Circuit has held in Amgen's favor on the validity of two patents that describe and claim Enbrel® (etanercept) and methods for making it.
The 2-1 decision by the U.S. Federal Circuit Court of Appeals in Washington, D.C. gives Amgen 31 years of exclusive rights to Enbrel, with protection for the patents extending to November 2028 and April 2029. Sandoz, a unit of Switzerland-based Novartis, said it may ask the U.S. Supreme Court to review the decision, which upheld an August 2019 ruling by a federal judge in New Jersey.
The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade. The court struck down one part of the new regulation, finding that using certain payments to third parties to determine a drug's regulated price went beyond the government's authority, but upheld the bulk of the rules. Canada published the final regulations in August last year, despite strong opposition from drug companies.
Regeneron hiked the price of its drug Eylea and spurred its sales by using a charitable foundation to cover Medicare patients’ out-of-pocket costs for the pricey drug, according to a civil suit.
An observational study of Amgen Inc's new osteoporosis drug Evenity released on Wednesday appears to confirm the increased risk of serious heart problems detected in clinical trials and included in the medicine's prescribing information. The drug, chemically known as romosozumab, won U.S. and European approval in 2019 for postmenopausal women with osteoporosis. Both U.S. and European regulators required a warning in the label of the potential risk of cardiovascular complications, such as heart attacks.